Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years
- 22 January 2009
- Vol. 27 (4) , 581-587
- https://doi.org/10.1016/j.vaccine.2008.10.088
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysisThe Lancet Infectious Diseases, 2007
- A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa RicaThe Journal of Infectious Diseases, 2005
- The carcinogenicity of human papillomavirus types reflects viral evolutionVirology, 2005
- Development and Duration of Human Papillomavirus Lesions, after Initial InfectionThe Journal of Infectious Diseases, 2005
- Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisBritish Journal of Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- The causal relation between human papillomavirus and cervical cancerJournal of Clinical Pathology, 2002
- Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in CarcinogenesisJNCI Journal of the National Cancer Institute, 2000
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Epidemiology of Genital Human Papillomavirus InfectionThe American Journal of Medicine, 1997